The results shown herein clearly indicate the contrary to the well-established assumptions that cell viability drastically deteriorates during the first 24 hours in culture after thawing and that infusion of thawed cell products containing DMSO as CPA in clinical or veterinary practice is associated with several types of mild to severe adverse reactions (ARs). In this sense, the authors of the present invention have unexpectedly found that MSCs cryopreserved by standard methods such as cell media, serum and10%(v/v) of DMSO, do not decline drastically in viability after thawing, maintaining a significant cell viability still 24 hours after thawing. Surprisingly as shown in example 8, these results are obtained when a basal media other than FBS (fetal bovine serum) is used. Moreover, as shown in the examples of the present invention, compositions comprising MSCs, a basal media other than FBS (fetal bovine serum) and 10% (v/v) of DMSO do not caused severe ARs.
展开▼
